8-K filed Jul 28, 2026 at 07:02 ET
Incyte reported Q2 2026 GAAP diluted EPS of $2.81 (vs consensus $2.15, +30.7% beat) and total revenue of $1.67B (vs consensus $1.49B, +12.1% beat), driven by a $246M one-time non-cash benefit from a CMS settlement on Opzelura. Excluding that benefit, total net sales grew 17% YoY. The company raised full-year total net sales guidance to $5.13B-$5.26B (from $4.77B-$4.94B) and Opzelura guidance to $1.05B-$1.10B, but also raised operating expense guidance sharply to reflect a $1.27B IPRD charge from the Vega Therapeutics acquisition. The core business (Jakafi +7%, Heme/Onc +69%) is solid, but the headline beat is heavily inflated by a one-time item, and the massive expense guidance increase clouds the forward earnings picture. The stock will likely trade on the raised sales guidance and pipeline progress, but the non-recurring nature of the CMS benefit tempers the bullish read-through for sustainable earnings power.